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More Questions Than Answers?I appreciate the recent paper by Arbustini et al. (1) in which they
propose a descriptive nosology that combines morphofunctional
trait and organ/system involvement with familial inheritance
pattern, identiﬁed genetic defect, or other etiologies. In my
opinion, a real revolution for clinical geneticists was the introduc-
tion of the concept of diagnostic “red ﬂags” made by Dr. Arbustini,
clinical markers that can guide the genetic research to a speciﬁc
gene (for example, atrioventricular block for the lamin A/C gene or
increased serum creatine phosphokinase for dystrophin gene
defects). On the basis of these red ﬂags, the authors proposed this
new classiﬁcation, which is much more detailed with respect to the
previous American and European attempts (2,3).
This new approach seems to be useful for many inherited car-
diomyopathies but, as underlined by the editorial by Elliott (4),
it is difﬁcult to apply to arrhythmogenic right ventricular dysplasia/
cardiomyopathy, because even the epsilon wave, which was for
many years considered the marker of the disease, can represent a red
ﬂag only when it is present at electrocardiography. Nowadays, it is
clear that the diagnosis of right ventricular dysplasia/cardiomyopathy
requires several red ﬂags (4,5). Finally, I hope that this new classiﬁ-
cation will open the doors to the unresolved problem of phenotype-
genotype correlation, considering ﬁrst of all families carrying the
same mutation; only in this case, I think it will be possible to use the
genetic data for the prognosis and therapy of inherited cardiomy-
opathies, even if it is well-known that many mutations are “private.”*Michele Pasotti, MD, PhD
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for a Phenotype-Genotype
Nomenclature of Cardiomyopathy
More Questions Than Answers?Dr. Pasotti, as most other cardiologists with expertise in cardio-
myopathies do (1), so aptly perceives the need for a more
comprehensive classiﬁcation that describes the phenotype and the
related “red ﬂag” involvement of other organs, and genetic (or
nongenetic) basis of the disease and supports the attempt of the
nosology proposed by MOGE(S) (morphofunctional characteristics
[M], organ involvement [O], genetic or familial inheritance pattern
[G], and an explicit etiological annotation [E], with details of ge-
netic defects or underlying disease cause [S]) (2). As commented by
Elliott (3) on the application of MOGE(S) (2), arrhythmogenic
right ventricular dysplasia/cardiomyopathy (ARVC/D) matches the
complexity of a disease in which the diagnostic criteria have been
debated and modiﬁed. In the original deﬁnition, the ARVC/D
was typically a right ventricular cardiomyopathy (4). The recently
modiﬁed Task Force Criteria recognizes ARVC/D as classic right
(the most common), biventricular, or predominantly left types (5).
The diagnosis relies on the demonstration of structural, func-
tional, and electrophysiological abnormalities that are caused by
or reﬂect the underlying histological changes. In both the original
and revised criteria, imaging-based morphological and functional
data (i.e., right ventricular size, akinesia, dyskinesia, or aneurysm,
dyssynchronous right ventricular contraction) remain the major
diagnostic contributors. In the routine clinical practice, the echo-
cardiographic or cardiac magnetic resonance (CMR) information
are, along with electrocardiographic features, the major alerting
traits. In the revised criteria, deﬁnite diagnosis is entertained when
2 major (M), or 1 major and 2 minor (m) criteria, or 4 minor cri-
teria from different categories are present, and the diagnosis of
the borderline ARVC/D is made when 1 major and 1 minor, or 3
minor criteria from different categories are present. A diagnosis of
possible ARVC/D is made if 1 major or 2 minor criteria from
different categories are observed. The application of these criteria
